Synageva BioPharma has met the enrollment target of 50 patients in its global Phase III trial of sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL Deficiency). To accommodate individuals still in the screening process, total enrollment will exceed the planned number of 50 patients, with the final patient expected to be randomized by the end of this year. As a result of this enrollment update, the company expects to report top-line results from the ARISE trial duri...